Among the many fascinating points discussed in this cross-therapy session are a number of key issues including:
||Response to antiplatelet drugs and how we might measure the effects of the drug
||Have we got the tests that allow us to assess the response to clopidegrel?
||What is the evidence for drug response having an impact on outcomes with peripheral vascular disease and procedures?
||In peripheral arterial stenting, is there a relationship between thrombosis and restenosis?
||In coronary treatment, are we comfortable in with how long and the intensity we continue antiplatelet therapy?
||Do we need further studies assessing the response to clopidegrel a wide range of therapeutic areas, or can we translate the studies from cardiology studies?
Robert Storey, Professor and Honorary Consultant in Cardiology, Department of Cardiovascular Science, University of Sheffield, UK (Chair)
Antonio Colombo, San Raffaele Hospital, Milan, Italy
Stavros Spiliopoulos, Patras University Hospital, Rion, Greece
Guillaume Taylor, Département d'Anesthésie Réanimation Urgencies, Fondation Ophtalmologique A de Rothschild, Paris, France
Jeff Daheln, Chief Scientific Officer, Accumetrics, US
Designed to support the continuous education of practicing physicians, this roundtable shares leading opinion and addresses the following questions and key educational objectives:
- Increase physician awareness of the multidisciplinary role of antiplatelet therapy
- Increase understanding of the role of platelet function testing in high-risk PCI
- Explain the emerging role of PFT in PAD
- Assess the role of antiplatelets in neuro-endovascular procedures
This round table discussion is intended for an international audience, specifically interventional cardiologists, interventional radiologists and aligned healthcare professional involved with antiplatelet therapy.
The Round Table Event was supported by Accumetrics.